✦ LIBER ✦

PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study

✍ Scribed by G.C. Jayson; J. Zweit; C. Mulatero; D. Hastings; P. Julyan; M. Ranson; J. Lawrance; A. McGown; A. Jackson; L. Hakannson; J. Wagstaff; G. Groenwegen; F. Lehmann; D. Levitt; T. Tang; H. Zweirzina

Book ID: 117657838
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 95 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)80467-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

A phase I pharmacokinetic (PK) and seria

A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 256 KB